<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170010</url>
  </required_header>
  <id_info>
    <org_study_id>Weight loss gut peptide study</org_study_id>
    <nct_id>NCT04170010</nct_id>
  </id_info>
  <brief_title>Long Term Effects of Weight Loss on Post-prandial Gut Hormone Responses and Meal Induced Thermogenesis</brief_title>
  <official_title>Postprandial Gut Hormone Responses and Meal-induced Thermogenesis After Non-surgical Long-term Weight Loss; Comparison With Surgically Treated Obese Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to examine post-prandial gut-hormone secretion, meal-induced thermogenesis and
      cardiovascular indices among conservatively managed compared to surgically managed obese
      individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a protocol for the study of post-prandial gut peptide response and meal-induced
      thermogenesis in a group of 15 conservatively managed (through diet and exercise) morbidly
      obese individuals. During two separate visits in the study site, anthropometric data will be
      collected, resting metabolic rate will be measured, and the patients will undergo a panel of
      cardiovascular examinations (heart rate variability, baroreflex sensitivity, heart
      ultrasound). On a separate occasion, they will consume a standardized test mixed meal and
      complete visual analog scales for the subjective assessment of hunger and fullness every 30
      minutes for 3 hours. At the same time points, blood samples will be collected for the
      consequent measurement of glucose, insulin, lipids, and gastrointestinal hormones.
      Additionally, immediately before and at 60', 120', 180' after the start of the consumption of
      the test meal, the resting metabolic rate of each participant will be assessed through
      indirect calorimetry, to quantify meal-induced thermogenesis. The observed induction of
      satiety and suppression of hunger, post prandial gut-peptide mobilization and change in
      metabolic rate will be compared to those of participants of trial no NCT03851874 (Morbidly
      obese patients that have undergone either Roux en Y gastric bypass or sleeve gastrectomy and
      participated in trial NCT03851874).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in postprandial Gut peptide (ghrelin, Gastric Inhibitory Peptide, Secretin, Peptide Tyrosine-Tyrosine - , Glucagon-like peptide - 1, Oxyntomodulin, Glicentin) responses</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in the cumulative postprandial response for the aforementioned gut hormones</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in resting metabolic rate following meal ingestion</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in the cumulative postprandial thermogenesis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in weight (percentage of weight following each intervention)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glycemia</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in postprandial glycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial insulinemia</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in the cumulative postprandial response for insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial triglyceridemia</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Change in the cumulative postprandial response for triglycerides</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in baroreflex sensitivity</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Changes in baroreflex sensitivity</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in heart rate variability</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Changes in heart rate variability</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in aortic distensibility</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Aortic distensibility will be evaluated by calculating the systolic and diastolic aortic diameter through M-mode echocardiography, 3 cm above the aortic valve, using the formula described in reference no 4 (PMID: 2282929)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Tei index</measure>
    <time_frame>8-10 years following primary weight-loss intervention</time_frame>
    <description>Changes in echocardiographic Tei index</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Conservatively managed group</arm_group_label>
    <description>Individuals with conservatively managed obesity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgically managed group</arm_group_label>
    <description>Individuals with a past history of bariatric surgery (Roux-en-Y gastric bypass/Sleeve gastrectomy) for the management of obesity</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Intervention group: participants of NCT03851874 trial Control group: conservatively
        (non-surgically, non-pharmaceutically) managed obese individuals among ambulatory patients
        of the obesity outpatient clinic of the 1st Department of Propaedeutic Internal Medicine
        (&quot;Laiko&quot; General Hospital)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For the conservatively managed cohort:

               1. Morbid obesity based on BMI &gt; 40kg/m2, managed exclusively with conservative
                  measures (hypocaloric diet and/or increased physical activity and/or behavioral
                  therapy)

               2. Age between 18 and 65 years

          -  For the bariatric cohort: Participation in NCT03851874 trial

        Exclusion Criteria:

          1. Serious and life threatening comorbidities (renal, cardiac, liver failure, or
             malignancy)

          2. Alcohol or other substance abuse

          3. Use of licenced or off-label weight loss medications during the past 6 months

          4. Concurrent psychiatric illness

          5. Known history of diabetes mellitus (remitted cases excluded)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandros Kokkinos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Department of Propaedeutic Medicine, NKUA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandros Kokkinos, MD, PhD</last_name>
    <phone>+302132061248</phone>
    <email>akokkinos@med.uoa.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Diabetes Clinical Research Laboratory, 1st Department of Propaedeutic Internal Medicine</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Kokkinos, MD, PhD</last_name>
      <phone>+302132061248</phone>
      <email>akokkinos@med.uoa.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Perakakis N, Kokkinos A, Peradze N, Tentolouris N, Ghaly W, Pilitsi E, Upadhyay J, Alexandrou A, Mantzoros CS. Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: Evidence from two independent trials. Metabolism. 2019 Dec;101:153997. doi: 10.1016/j.metabol.2019.153997. Epub 2019 Oct 28.</citation>
    <PMID>31672446</PMID>
  </reference>
  <reference>
    <citation>Liaskos C, Koliaki C, Alexiadou K, Argyrakopoulou G, Tentolouris N, Diamantis T, Alexandrou A, Katsilambros N, Kokkinos A. Roux-en-Y Gastric Bypass Is More Effective than Sleeve Gastrectomy in Improving Postprandial Glycaemia and Lipaemia in Non-diabetic Morbidly Obese Patients: a Short-term Follow-up Analysis. Obes Surg. 2018 Dec;28(12):3997-4005. doi: 10.1007/s11695-018-3454-y.</citation>
    <PMID>30112599</PMID>
  </reference>
  <reference>
    <citation>Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, Hashemi M, Adamo M, Finer N, Fiennes AG, Withers DJ, Batterham RL. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg. 2014 Feb;24(2):241-52. doi: 10.1007/s11695-013-1066-0.</citation>
    <PMID>23996294</PMID>
  </reference>
  <reference>
    <citation>Stefanadis C, Stratos C, Boudoulas H, Kourouklis C, Toutouzas P. Distensibility of the ascending aorta: comparison of invasive and non-invasive techniques in healthy men and in men with coronary artery disease. Eur Heart J. 1990 Nov;11(11):990-6.</citation>
    <PMID>2282929</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Alexandros Kokkinos</investigator_full_name>
    <investigator_title>Associate Professor in Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Weight loss</keyword>
  <keyword>Gut peptides</keyword>
  <keyword>Meal-induced thermogenesis</keyword>
  <keyword>Glycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

